TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$150 Million

Arcutis Biotherapeutics, Inc.

Follow-on Offering

Bookrunner, February 2024

Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. (“Arcutis” or the “Company”) (NASDAQ: ARQT) is commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Their current portfolio is comprised of highly differentiated topical and systemic treatments with significant potential to treat immune-mediated dermatological diseases and conditions.